April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA82
Academic Journal
Clinical trials suggest treating genotype 1 hepatitis C with combination treatment for 12 months and genotype 2/3 for 6 months. However, this prolonged course of treatment reduces compliance and puts enormous strain on budgets, thereby limiting its use. This study has shown that 3 months treatment may be adequate for patients with genotype 2/3 hepatitis C; however the higher role of relapse in genotype 1 may indicate the need for 6-12 months combination therapy.


Related Articles

  • Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Bartels, Doug J.; Yi Zhou; Zhang, Eileen Z.; Marcial, Michelle; Byrn, Randal A.; Pfeiffer, Thomas; Tigges, Ann M.; Adiwijaya, Bambang S.; Chao Lin; Kwong, Ann D.; Kieffer, Tara L. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p800 

    Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response. Methods....

  • Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. El Awady, Mostafa K.; El Din, Noha G. Badr; El Garf, Wael T.; Youssef, Samar S.; Omran, Moataza H.; El Abd, Jasmin; Goueli, Said A. // Cancer Cell International;2006, Vol. 6, p18 

    Background: Hepatitis C (HCV) viral infection is a serious medical problem in Egypt and it has a devastating impact on the Egyptian economy. It is estimated that over 15% of Egyptians are infected by the virus and thus finding a cure for this disease is of utmost importance. Current therapies...

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p6 

    This section offers news related to clinical trials. Dosing of ANA598 in patients chronically infected with hepatitis C virus has been started by Anadys Pharmaceuticals Inc. in a Phase Ib study. Enrollment has been completed in Chelsea Therapeutics International Limited's Phase II trial...

  • Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Spada, E.; Mele, A.; Berton, A.; Ruggeri, L.; Ferrigno, L.; Garbuglia, A. R.; Perrone, M. P.; Girelli, G.; Del Porto, P.; Piccolella, E.; Mondelli, M. U.; Amoroso, P.; Cortese, R.; Nicosia, A.; Vitelli, A.; Folgori, A. // Gut;Nov2004, Vol. 53 Issue 11, p1673 

    Background/Aims: Hepatitis C virus (HCV) infection results in a high frequency of chronic disease. The aim of this study was to identify early prognostic markers of disease resolution by performing a comprehensive analysis of viral and host factors during the natural course of acute HCV...

  • ANA773.  // Biotech Financial Reports;Sep2009, Vol. 16 Issue 9, p8 

    The article offers information on the phase I clinical trial of ANA773, an oral inducer of endogenous interferons acting via the toll like receptor 7 pathway, by Anadys Pharmaceuticals Inc. in San Diego, California. It notes the company' report of evidence of viral load reduction in the majority...

  • Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. Kasahara, Akinori; Hiraide, Atsushi; Tomita, Naruya; Iwahashi, Hiromi; Imagawa, Akihisa; Ohguro, Nobuyuki; Yamamoto, Shuji; Mita, Eiji; Hayashi, Norio // Journal of Gastroenterology;2004, Vol. 39 Issue 11, p1106 

    Retinal abnormalities, including retinal hemorrhage and “cotton-wool” spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of...

  • Hepatitis C in Childhood. Arora, N. K.; Das, M. K.; Mathur, P.; Mishra, R. // International Seminars in Pediatric Gastroenterology & Nutrition;Dec2004, Vol. 12 Issue 4, p3 

    Presents clinical information concerning hepatitis C virus (HCV) infection in children. Genotypes of HCV that have been isolated; Epidemiology of HCV; Therapeutic options for HCV infections.

  • Efficacy of interferon therapy for aged patients with chronic hepatitis C. Arase, Yasuji; Kumada, Hiromitsu // Journal of Gastroenterology;2004, Vol. 39 Issue 11, p1123 

    The article reports on the efficacy of interferon therapy for aged patients with chronic hepatitis C. Chronic hepatitis C infection can be associated with progressive liver disease that may evolve insidiously into liver cirrhosis and carriers an increased risk of hepatocellular carcinoma (HCC)....

  • Treating Chronic Hepatitis C Patients With Psychiatric Disorders: An Uphill Battle. Cheung, Ramsey; Ahmed, Aijaz // American Journal of Gastroenterology;Jan2001, Vol. 96 Issue 1, p3 

    Focuses on hepatitis C virus (HCV) infection. Side effects of taking interferon for the treatment of HCV; Prevalence of HCV infection; Discussion on the neuropsychiatric side effects of interferon therapy in chronic hepatitis C veterans.


Read the Article


Sign out of this library

Other Topics